semaglutide and dialysis Kidney care is entering a whole new era π With the 2025 FDA approval of Ozempic (semaglutide) to help slow chronic kidney disease in people with type 2 diabetes, patients now have Semaglutide 1.0 mg (Ozempic) Reduced
Description
GLP-1
But from a neuropathology perspective, the evidence is thin
Future clinical trials should aim to distinguish the direct analgesic effects of GLP-1RAs from their metabolic benefits and explore their broader applications in pain conditions
It looked like clickbait
Pharma leaders reveal how blockbuster therapies are reshaping M&A priorities and portfolios.
Who This Is For
